Xarelto found to improve patient outcomes with PAD and CAD

Findings from the PAD analysis showed that Xarelto (rivaroxaban) 2.5mg twice daily, plus aspirin 100mg once daily substantially reduced the risk of major amputation by 70 percent and the risk of experiencing major adverse cardiovascular events (MACE), major adverse limb events (MALE) and major amputation by 31 percent compared with aspirin 100mg once daily alone.

Additional data for this treatment regimen in patients with PAD demonstrated a 28 percent relative risk reduction in the primary efficacy outcome of MACE, and a 46 percent reduction in MALE compared with aspirin 100mg once daily alone. The firms also noted that bleeding rates were low, and while major bleeding was increased, there was no significant differences in fatal bleeding, non-fatal intracranial bleeding or bleeding into a critical organ between any of the treatment groups. Also, the Xarelto regimen demonstrated an improvement in net clinical benefit - defined as the combined outcome of MACE, MALE and major amputation, balanced with fatal bleeding or symptomatic bleeding into a critical organ - in both patient populations compared with aspirin alone (28 percent in patients with PAD, and 23 percent in patients with CAD.